Literature DB >> 25321622

Enhanced individual trabecular repair and its mechanical implications in parathyroid hormone and alendronate treated rat tibial bone.

Allison R Altman, Chantal M J de Bakker, Wei-Ju Tseng, Abhishek Chandra, Ling Qin, X Sherry Liu.   

Abstract

Combined parathyroid hormone (PTH) and bisphosphonate (alendronate-ALN) therapy has recently been shown to increase bone volume fraction and plate-like trabecular structure beyond either monotherapy. To identify the mechanism through which plate-like structure was enhanced, we used in vivo microcomputed tomography (μCT) of the proximal tibia metaphysis and individual trabecular dynamics (ITD) analysis to quantify connectivity repair (incidences of rod connection and plate perforation filling) and deterioration (incidences of rod disconnection and plate perforation). Three-month-old female, intact rats were scanned before and after a 12 day treatment period of vehicle (Veh, n = 5), ALN (n = 6), PTH (n = 6), and combined (PTH+ALN, n = 6) therapy. Additionally, we used computational simulation and finite element (FE) analysis to delineate the contributions of connectivity repair or trabecular thickening to trabecular bone stiffness. Our results showed that the combined therapy group had greater connectivity repair (5.8 ± 0.5% connected rods and 2.0 ± 0.3% filled plates) beyond that of the Veh group, resulting in the greatest net gain in connectivity. For all treatment groups, increases in bone volume due to thickening (5-31%) were far greater than those due to connectivity repair (2-3%). Newly formed bone contributing only to trabecular thickening caused a 10%, 41%, and 69% increase in stiffness in the ALN, PTH, and PTH+ALN groups, respectively. Moreover, newly formed bone that led to connectivity repair resulted in an additional improvement in stiffness, with the highest in PTH+ALN (by an additional 12%), which was significantly greater than either PTH (5.6%) or ALN (4.5%). An efficiency ratio was calculated as the mean percent increase in stiffness divided by mean percent increase in BV for either thickening or connectivity repair in each treatment. For all treatments, the efficiency ratio of connectivity repair (ALN: 2.9; PTH: 3.4; PTH+ALN: 4.4) was higher than that due to thickening (ALN: 2.0; PTH: 1.7; PTH+ALN: 2.2), suggesting connectivity repair required less new bone formation to induce larger gains in stiffness. We conclude that through rod connection and plate perforation filling PTH+ALN combination therapy improved bone stiffness in a more efficient and effective manner than either monotherapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25321622      PMCID: PMC5082207          DOI: 10.1115/1.4028823

Source DB:  PubMed          Journal:  J Biomech Eng        ISSN: 0148-0731            Impact factor:   2.097


  48 in total

1.  The relationship between three-dimensional connectivity and the elastic properties of trabecular bone.

Authors:  J H Kinney; A J Ladd
Journal:  J Bone Miner Res       Date:  1998-05       Impact factor: 6.741

2.  Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice.

Authors:  Rana Samadfam; Qingwen Xia; David Goltzman
Journal:  J Bone Miner Res       Date:  2007-01       Impact factor: 6.741

3.  Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Authors:  Felicia Cosman; Erik Fink Eriksen; Chris Recknor; Paul D Miller; Núria Guañabens; Christian Kasperk; Philemon Papanastasiou; Aimee Readie; Hanumantha Rao; Jürg A Gasser; Christina Bucci-Rechtweg; Steven Boonen
Journal:  J Bone Miner Res       Date:  2011-03       Impact factor: 6.741

4.  Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.

Authors:  Joel S Finkelstein; Jason J Wyland; Hang Lee; Robert M Neer
Journal:  J Clin Endocrinol Metab       Date:  2010-02-17       Impact factor: 5.958

5.  PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats.

Authors:  Annemarie Brüel; Jens Bay Vegger; Anders Christer Raffalt; Jens Enevold Thaulov Andersen; Jesper Skovhus Thomsen
Journal:  Bone       Date:  2012-12-11       Impact factor: 4.398

6.  Contributions of trabecular rods of various orientations in determining the elastic properties of human vertebral trabecular bone.

Authors:  X Sherry Liu; X Henry Zhang; X Edward Guo
Journal:  Bone       Date:  2009-04-18       Impact factor: 4.398

7.  Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

Authors:  Felicia Cosman; Robert A Wermers; Christopher Recknor; Karen F Mauck; Li Xie; Emmett V Glass; John H Krege
Journal:  J Clin Endocrinol Metab       Date:  2009-07-07       Impact factor: 5.958

Review 8.  Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

Authors:  Michael McClung; Steven T Harris; Paul D Miller; Douglas C Bauer; K Shawn Davison; Larry Dian; David A Hanley; David L Kendler; Chui Kin Yuen; E Michael Lewiecki
Journal:  Am J Med       Date:  2012-11-20       Impact factor: 4.965

9.  Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells.

Authors:  Gustavo Duque; Daniel Rivas
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

Review 10.  Parathyroid hormone: a double-edged sword for bone metabolism.

Authors:  Ling Qin; Liza J Raggatt; Nicola C Partridge
Journal:  Trends Endocrinol Metab       Date:  2004-03       Impact factor: 12.015

View more
  7 in total

1.  Adaptations in the Microarchitecture and Load Distribution of Maternal Cortical and Trabecular Bone in Response to Multiple Reproductive Cycles in Rats.

Authors:  Chantal Mj de Bakker; Allison R Altman-Singles; Yihan Li; Wei-Ju Tseng; Connie Li; X Sherry Liu
Journal:  J Bone Miner Res       Date:  2017-02-09       Impact factor: 6.741

2.  Intermittent Parathyroid Hormone After Prolonged Alendronate Treatment Induces Substantial New Bone Formation and Increases Bone Tissue Heterogeneity in Ovariectomized Rats.

Authors:  Allison R Altman-Singles; Yonghoon Jeong; Wei-Ju Tseng; Chantal Mj de Bakker; Hongbo Zhao; Carina Lott; Juhanna Robberts; Ling Qin; Lin Han; Do-Gyoon Kim; X Sherry Liu
Journal:  J Bone Miner Res       Date:  2017-06-13       Impact factor: 6.741

3.  Structural Adaptations in the Rat Tibia Bone Induced by Pregnancy and Lactation Confer Protective Effects Against Future Estrogen Deficiency.

Authors:  Chantal Mj de Bakker; Yihan Li; Hongbo Zhao; Laurel Leavitt; Wei-Ju Tseng; Tiao Lin; Wei Tong; Ling Qin; X Sherry Liu
Journal:  J Bone Miner Res       Date:  2018-08-13       Impact factor: 6.741

4.  Comparison of parathyroid hormone and strontium ranelate in combination with whole-body vibration in a rat model of osteoporosis.

Authors:  D B Hoffmann; S Sehmisch; A M Hofmann; C Eimer; M Komrakova; D Saul; M Wassmann; K M Stürmer; M Tezval
Journal:  J Bone Miner Metab       Date:  2016-01-29       Impact factor: 2.626

5.  Peak trabecular bone microstructure predicts rate of estrogen-deficiency-induced bone loss in rats.

Authors:  Yihan Li; Wei-Ju Tseng; Chantal M J de Bakker; Hongbo Zhao; Rebecca Chung; X Sherry Liu
Journal:  Bone       Date:  2021-01-22       Impact factor: 4.398

6.  Spatiotemporal Changes of Calcitonin Gene-Related Peptide Innervation in Spinal Fusion.

Authors:  Xiao-Yi Zhou; Xi-Ming Xu; Sui-Yi Wu; Fei Wang; Yi-Lin Yang; Ming Li; Xian-Zhao Wei
Journal:  Biomed Res Int       Date:  2016-11-21       Impact factor: 3.411

Review 7.  Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives.

Authors:  Chenggui Zhang; Chunli Song
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.